What is the primary purpose of this 8-K filing for Cencora (COR)?

This 8-K filing announces a material definitive agreement where Cencora (COR), formerly AmerisourceBergen, is acquiring the majority of Walgreens Boots Alliance's (WBA) Alliance Healthcare businesses. It details the terms of the acquisition, the strategic rationale, and related agreements, including extensions of existing distribution contracts.

What is the total value of the acquisition and how will Cencora fund it?

The acquisition is valued at approximately $6.5 billion, consisting of $6.275 billion in cash and 2 million shares of Cencora's common stock. Cencora expects to fund the cash portion through a combination of existing cash reserves and new debt financing, for which it has secured $3.025 billion in bridge financing commitments.

Are there any key strategic benefits or implications for Cencora investors?

The acquisition significantly expands Cencora's global footprint and strengthens its position in pharmaceutical distribution. The extension of distribution agreements with WBA through 2029 provides long-term revenue visibility. The agreement also paves the way for exploring further strategic initiatives to enhance growth and operational efficiencies, potentially leading to increased profitability and market share.

What are the conditions required for this transaction to close?

The transaction is subject to the satisfaction of customary closing conditions, which primarily include obtaining the necessary regulatory approvals. The filing does not specify all conditions, but these are standard for significant M&A activities.

COR 8-K: Material Agreements & Regulation FD

Summary

Cencora, Inc. (COR), formerly AmerisourceBergen Corporation, announced a significant strategic transaction with Walgreens Boots Alliance, Inc. (WBA) on January 6, 2021. The core of this agreement involves COR's acquisition of the majority of WBA's Alliance Healthcare businesses for approximately $6.5 billion, comprising $6.275 billion in cash and 2 million shares of COR common stock. This transaction is expected to be funded through existing cash and new debt financing, with bridge financing commitments secured. The deal also includes a three-year extension of existing distribution agreements with WBA through 2029, strengthening the long-term relationship between the two entities. Additionally, COR will supply branded and generic products to WBA's Boots UK Ltd. post-acquisition and will explore further strategic initiatives for growth and efficiency. This substantial acquisition marks a pivotal moment for Cencora, significantly expanding its global reach and service offerings, particularly in the wholesale distribution of pharmaceutical products. The transaction is subject to customary closing conditions, including regulatory approvals. Investors should note that the deal's success hinges on these approvals and the effective integration of the acquired Alliance Healthcare businesses. The filing also references an Amended and Restated Shareholders Agreement that will adjust WBA's permitted ownership percentage of COR common stock.

Key Highlights

1Cencora (COR) to acquire the majority of Walgreens Boots Alliance's (WBA) Alliance Healthcare businesses for approximately $6.5 billion ($6.275 billion cash, 2 million COR shares).
2Transaction includes a three-year extension of key distribution agreements between COR and WBA through 2029.
3COR will supply branded and generic pharmaceutical products to WBA's Boots UK Ltd. following the acquisition.
4The deal is subject to customary closing conditions, including regulatory approvals.
5COR expects to fund the cash portion of the acquisition through cash on hand and new debt financing, with $3.025 billion in bridge financing commitments obtained.
6An Amended and Restated Shareholders Agreement will be entered into, adjusting WBA's permitted stock ownership in COR.
7WBA's operations in China, Italy, and Germany are excluded from this transaction.

Cencora, Inc. 8-K Report, Material Agreement (Jan 8, 2021)

Summary

Key Highlights

Frequently Asked Questions